HOCl is one of the most thoroughly studied antimicrobials in medicine — recognized by the WHO and documented across decades of peer-reviewed literature. Below is a curated starting point from independent, publicly available sources.
Added in 2025 as an environmental disinfectant — the WHO’s official listing entry.
Read the source →The primary submission and evidence dossier evaluated by the WHO Expert Committee.
Read the source →A peer-reviewed review of HOCl’s efficacy and safety across wound care, infection prevention, and inflammatory skin conditions.
Read the source →An in-vitro study of HOCl’s activity against micro-organisms with and without biofilm.
Read the source →A critical review of the ecological and human-health impacts of the QAC disinfectants HOCl is positioned to replace.
Read the source →Peer-reviewed evidence on the reproductive and developmental risks associated with widely used QAC disinfectants.
Read the source →Beyond the published literature, MedeSol sponsors original HOCl research and presents its work where clinicians, researchers, and industry gather — engagement you won’t find behind other HOCl labels.
A MedeSol-sponsored study on hypochlorous acid for wound care in mycetoma, a WHO-recognized neglected tropical disease, co-authored by MedeSol CSO Dr. Jeffrey Williams and published in the peer-reviewed literature:
Sulaiman S, Osman E, Nour B, et al. “Hypochlorous Acid for Community Level Wound Management: A New Horizon in Public Health.” Indian Journal of Public Health Research & Development, 2026;17(3):95–102.
Read the study →In 2026, the University of Washington Bothell School of STEM named MedeSol CSO Dr. Jeffrey Williams the inaugural recipient of its STEM Partnership Impact Award, recognizing his mentorship and research partnership with the School and Dr. Lori Robins. Read the UW Bothell announcement →
MedeSol shares detailed technical, scientific, and regulatory documentation with partners, licensees, and prospective collaborators under discussion.
Request more information →